دورية أكاديمية
Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions.
| العنوان: | Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions. |
|---|---|
| المؤلفون: | Manzor Mitrzyk B; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Plegue MA; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA., Kadri R; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA., Danak SU; Department of Family & Community Medicine, Penn State Health, Milton S Hershey Medical Center, Hershey, PA 17033, USA., Hubbard JD; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Kaip EA; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Roberson DN; College of Medicine, University of Florida, Gainesville, FL 32610, USA., Roy S; School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA., Guetterman TC; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA., Ellingrod VL; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Farris KB; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Ruffin Iv MT; Department of Family & Community Medicine, Penn State Health, Milton S Hershey Medical Center, Hershey, PA 17033, USA., Klinkman MS; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA., Buis LR; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA. |
| المصدر: | Personalized medicine [Per Med] 2021 May; Vol. 18 (3), pp. 233-240. Date of Electronic Publication: 2021 Mar 17. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Country of Publication: England NLM ID: 101238549 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-828X (Electronic) Linking ISSN: 17410541 NLM ISO Abbreviation: Per Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Future Medicine, c2004- |
| مواضيع طبية MeSH: | Attitude of Health Personnel*, Attention Deficit Disorder with Hyperactivity/*drug therapy , Cytochrome P-450 Enzyme System/*genetics , Depression/*drug therapy , Pharmacogenomic Testing/*statistics & numerical data, Adult ; Attention Deficit Disorder with Hyperactivity/genetics ; Comorbidity ; Depression/genetics ; Female ; Humans ; Insurance Coverage ; Male ; Mental Health ; Middle Aged |
| مستخلص: | Aim: We sought to explore how early adopters use pharmacogenomic (PGx) testing for treating depression and attention-deficit/hyperactivity disorder. Patients & methods: Prescribers of the Informed PGx (Progenity, Inc., Ann Arbor, MI 48108, USA) test completed a phone survey assessing use of PGx testing for different scenarios. We conducted a qualitative thematic text analysis of transcribed audio recordings of open-ended responses (n = 62). Results: PGx testing was used when treating multiple comorbidities or resistant disease, and to ease patients' concerns with future therapy. Use of PGx testing is influenced by insurance coverage, interpretability of results and results turnaround time. Conclusion: Prescribers used PGx tests to modify medications for complex patients with depression, attention-deficit/hyperactivity disorder and other disorders to alleviate concerns related to adverse effects and lack of effectiveness. |
| فهرسة مساهمة: | Keywords: altered metabolizer status; clinical decision support; clinical scenarios; cost; early adopters; insurance coverage; medication selection; qualitative; training |
| المشرفين على المادة: | 9035-51-2 (Cytochrome P-450 Enzyme System) |
| تواريخ الأحداث: | Date Created: 20210317 Date Completed: 20211224 Latest Revision: 20211224 |
| رمز التحديث: | 20240628 |
| DOI: | 10.2217/pme-2020-0084 |
| PMID: | 33728996 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-828X |
|---|---|
| DOI: | 10.2217/pme-2020-0084 |